WO2003068247A1 - Eye installation based on iodine anions - Google Patents
Eye installation based on iodine anions Download PDFInfo
- Publication number
- WO2003068247A1 WO2003068247A1 PCT/SK2003/000004 SK0300004W WO03068247A1 WO 2003068247 A1 WO2003068247 A1 WO 2003068247A1 SK 0300004 W SK0300004 W SK 0300004W WO 03068247 A1 WO03068247 A1 WO 03068247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- weight percent
- solution
- eye
- iodine anion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the solution relates to eye instillation based on iodine anions.
- Iodine found its application in ophtalmology in the treatment of both infectious and non-infectious (degenerative) diseases, including prophylaxis of the cataract.
- the application of the iodine anion and of organic iodine compounds in an experiment has confirmed an inhibitory effect upon arteriosclerosis and, at the same time, it has been proved that iodine anions facilitate the solvability of colloids, due to which the viscosity of blood decreases.
- the essence of the submitted solution of eye instillation is that it contains from 0.01 to 5 weight percent of potassium iodide as an active substance, from 0.0005 to 0.1 weight percent of a conservation agent, further from 0.001 to 2 weight percent of ancillary substances maintaining pH of the solution in the range from 5 to 8.0, and the rest to 100 weight percent is sterilized distilled water.
- the essence of the submitted solution is an eye instillation based on iodine ions as an active substance with a content of suitable conservation agent and of ancillary substances ensuring the required stability of the medicine.
- the eye instillation may contain also an addition of another active substance of sodium iodide in content from 0.01 to 5 weight percent and possibly also substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s, their content ranging from 0.01 to 5 weight percent individually or in mixture.
- the conservation agent in the instillation is chlorhexidine acetate or chlorhexidine gluconate, chlorbutanol or carbentho pendetinium bromide, which are substances compatible with iodine ions.
- the substances maintaining pH in the range from 5 to 8.0 are sodium chloride, boric acid, sodium tetraborate, sodium acetate, sodium edetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium tiosulphate, sodium citrate, citric acid individually or in mixture.
- the instillation may contain also substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s, such as hydroxypropylmethylcellulose, polyvinyl alcohol, monooleate polyoxyethylenesorbitan or carboxyvinyl polymer individually or in mixture.
- Figure 1 represents a chromatographic scan of chlorhexidine detection in an eye instillation containing 2 weight percent of KI.
- the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
- composition for one package a) Composition for one package:
- composition for one package :
- the amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
- composition for one package potassium iodide 0,50000 g sodium iodide 0,50000 g boric acid 0,20000 g sodium tertaborate 0,20000 g sodium tiosulphate 0,20000 g sodium edetate 0,20000 g carbetho pendetinium bromide 0,05000 g sterilized distilled water ad 10 ml ⁇
- potassium iodide 0,50000 g sodium iodide 0,50000 g boric acid 0,20000 g sodium tertaborate 0,20000 g sodium tiosulphate 0,20000 g sodium
- potassium iodide 0,50000 g sodium iodide 0,50000 g sodium hydrogen phosphate 0,20000 g sodium dihydrogen phosphate 0,20000 g sodium tiosulphate 0,20000 g chlorhexidine acetate 0,05000 g sterilized distilled water ad 10 ml
- potassium iodide 0,50000 g citric acid 0,20000 g sodium citrate 0,20000 g monooleate polyoxyetliylensorbitan 0,50000 g hydroxypropylmethylceluulose 0,20000 g chlorhexidine acetate 0,05000 g sterilized distilled water ad 10 ml
- the eye instillation based on iodine anions pursuant to the submitted solution with iodine anions in the form of potassium iodide or potassium and sodium iodides as an active substance can be utilized in ophtalmology in such indications as the support of resorption processes in the eye, in particular of exudates, cataracts of diverse ethiology, atero- and arteriosclerotic changes of the vessels of the retina and chorioidea, degenerative processes on the retina, beginning cataracts, mucotic conjuntivites and ceratidites.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The essence of submitted solution of eye instillation is that it contains from 0.01 to 5 weight percent of potassium iodide as an active substance, from 0.0005 to 0.1 weight percent of a conservation agent, further from 0.001 to 2 weight percent of ancillary substances maintaining pH of the solution in the range from 5 to 8.0 and the rest to 100 weight percent is sterilized distilled water.
Description
Eye Instillation Based on Iodine Anions
Technical Field
The solution relates to eye instillation based on iodine anions.
State of the Art
In the thirties of the 20* century, Iodine found its application in ophtalmology in the treatment of both infectious and non-infectious (degenerative) diseases, including prophylaxis of the cataract. The application of the iodine anion and of organic iodine compounds in an experiment has confirmed an inhibitory effect upon arteriosclerosis and, at the same time, it has been proved that iodine anions facilitate the solvability of colloids, due to which the viscosity of blood decreases.
Also the manifestations of ageing - arteriosclerosis - are related first of all with the decrease in colloid dispersity. Dysfunction, which is due to sclerotic changes of the blood vessels in the eye, can be affected favourably by means of potassium iodide. It is probable that the salts of iodine, by inliibiting this process, mitigate the development of arteriosclerosis. On the basis of this it is believed that they affect also the cell membranes, which brmgs about an improvement of the metabolic processes.
In the treatment of the aforementioned diseases, therapeutic practice has long used an iodine instillation with potassium iodide and an eye instillation with potassium and sodium iodides containing tiomersal as a conservation agent. These substance, however, have not proved to be sufficiently stable. Since tiomersal is incompatible with iodine ions, it decomposes rapidly due to which its content in the final substance can not be determined. In addition, gradual increase in the acidity of the substance takes place.
The Background of the Technical Solution
The essence of the submitted solution of eye instillation is that it contains from 0.01 to 5 weight percent of potassium iodide as an active substance, from 0.0005 to 0.1 weight percent of a conservation agent, further from 0.001 to 2 weight percent of ancillary substances maintaining pH of the solution in the range from 5 to 8.0, and the rest to 100 weight percent is sterilized distilled water. Thus, the essence of the submitted solution is an eye instillation
based on iodine ions as an active substance with a content of suitable conservation agent and of ancillary substances ensuring the required stability of the medicine.
The eye instillation may contain also an addition of another active substance of sodium iodide in content from 0.01 to 5 weight percent and possibly also substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s, their content ranging from 0.01 to 5 weight percent individually or in mixture.
The conservation agent in the instillation is chlorhexidine acetate or chlorhexidine gluconate, chlorbutanol or carbentho pendetinium bromide, which are substances compatible with iodine ions.
The substances maintaining pH in the range from 5 to 8.0 are sodium chloride, boric acid, sodium tetraborate, sodium acetate, sodium edetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium tiosulphate, sodium citrate, citric acid individually or in mixture.
The instillation may contain also substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s, such as hydroxypropylmethylcellulose, polyvinyl alcohol, monooleate polyoxyethylenesorbitan or carboxyvinyl polymer individually or in mixture.
The eye instillation pursuant to the submitted solution exhibits good physical and chemical stability. Since chlorhexidine is not incompatible with iodine ions, the content of this conservation agent can be determined in the whole range of its antimicrobial activity. Stable topical acidity of the solution has been verified, which allows to utilize these prescriptions in the conditions of mass production.
Figures in Drawings
Figure 1 represents a chromatographic scan of chlorhexidine detection in an eye instillation containing 2 weight percent of KI.
Examples of embodiments Example 1
Weighed amounts of components ( according to the production batch size ) are dissolved in sterilized distilled water under aseptic conditions. After having dissolved them
sterilized distilled water is added to the solution up to the specified volume. The resulting solution is sterilized by filtration througli a membrane filter with 0.2 μm mesh and immediately dosed into sterile vials and sealed with sterile seals under aseptic conditions. The sealed vials are labeled and packed into specified packages.
The amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
a) Composition for one package:
potassium iodide 0,01000 g sodium iodide 0,01000 g sodium chloride 0,00010 g sodium tiosulphate 0,00010 g monooleate polyoxyethylensorbitan 0,00100 g sodium edetate 0,00010 g hydroxypropylmethylcellulose 0,00100 g chlorhexidine acetate 0,00005 g sterilized distilled water ad 10 ml
b) Composition for one package:
potassium iodide 0,01000 g sodium chloride 0,00010 g sodium tiosulphate 0,00010 g monooleate polyoxyethylensorbitan 0,00100 g sodium edetate 0,00010 g polyvinyl alcohol 0,00100 g chlorbutanol 0,00005 g sterilized distilled water ad 10 ml
C) Composition for one package:
potassium iodide 0,01000 g sodium iodide 0,01000 g boric acid 0,00010 g sodium tertaborate 0,00010 g sodium tiosulphate 0,00010 g sodium edetate 0,00010 g carbetho pendetinium bromide 0,00005 g sterilized distilled water ad 10 ml
Composition for one package:
potassium iodide 0,01000 g sodium iodide 0,01000 g sodium hydrogen phosphate 0,00010 g sodium dihydrogen phosphate 0,00010 g sodium tiosulphate 0,00010 g chlorhexidine gluconate 0,00005 g sterilized distilled water ad 10 ml
β) Composition for one package:
potassium iodide 0,01000 g citric acid 0,00010 g sodium citrate 0,00010 g monooleate polyoxyethylensorbitan 0,00100 g hydroxypropylmethylcellulose 0,00100 g chlorhexidine acetate 0,00005 g sterilized distilled water ad 10 ml
) Composition for one package:
potassium iodide 0,01000 g sodium iodide 0,00010 g sodium tiosulphate 0,00010 g sodium edetate 0,00010 g chlorhexidine acetate 0,00005 g sterilized diestilled water ad 10 ml
g) Composition for one package: potassium iodide 0,01000 g sodium iodide 0,01000 g sodium tiosulphate 0,00010 g monooleate polyoxyethylensorbitan 0,00100 g sodium edetate 0,00010 g chlorhexidine gluconate 0,00005 g sterilized distilled water ad 10 ml
Example 2
Weighed amounts of components (according to the production batch size) are dissolved in sterilized distilled water under aseptic conditions. After having dissolved them sterilized distilled water is added to the solution up to the specified volume. The resulting solution is sterilized by filtration through a membrane filter with 0.2 μm mesh and immediately dosed into sterile vials and sealed with sterile seals under aseptic conditions. The sealed vials are labeled and packed into specified packages.
The amounts of components of a production batch are a linear function of the amounts per one package, i. e. 10 ml.
a) Composition for one package: potassium iodide 0,50000 g sodium iodide 0,50000 g sodium chloride 0,20000 g sodium tiosulphate 0,20000 g monooleate polyoxyethylensorbitan 0,50000 g sodium edetate 0,20000 g hydroxypropylmethylcellulose 0,50000 g chlorhexidine gluconate 0,05000 g sterilized distilled water ad 10 ml
b) Composition for one package: potassium iodide 0,50000 g sodium chloride 0,20000 g sodium tiosulphate 0,20000 g monooleate polyoxyethylensorbitan 0,50000 g sodium edetate 0,20000 g polyvinyl alcohol 0,50000 g chlorbutanol 0,05000 g sterilized distilled water ad 10 ml
c) Composition for one package: potassium iodide 0,50000 g sodium iodide 0,50000 g boric acid 0,20000 g sodium tertaborate 0,20000 g sodium tiosulphate 0,20000 g sodium edetate 0,20000 g carbetho pendetinium bromide 0,05000 g sterilized distilled water ad 10 ml
Φ Composition for one package:
potassium iodide 0,50000 g sodium iodide 0,50000 g sodium hydrogen phosphate 0,20000 g sodium dihydrogen phosphate 0,20000 g sodium tiosulphate 0,20000 g chlorhexidine acetate 0,05000 g sterilized distilled water ad 10 ml
e) Composition for one package:
potassium iodide 0,50000 g citric acid 0,20000 g sodium citrate 0,20000 g monooleate polyoxyetliylensorbitan 0,50000 g hydroxypropylmethylceluulose 0,20000 g chlorhexidine acetate 0,05000 g sterilized distilled water ad 10 ml
f) Composition for one package:
potassium iodide 0,50000 g sodium iodide 0,20000 g sodium tiosulphate 0,20000 g sodium edetate 0,20000 g chlorhexidine glukonate 0,05000 g sterilized distilled water ad 10 ml
g) Composition for one package: potassium iodide 0,50000 g sodium iodide 0,50000 g sodium tiosulphate 0,20000 g monooleate polyoxyethylensorbitan 0,50000 g sodium edetate 0,20000 g chlorhexidine acetate 0,05000 g sterilized distilled water ad 10 ml
industrial Applicability
The eye instillation based on iodine anions pursuant to the submitted solution with iodine anions in the form of potassium iodide or potassium and sodium iodides as an active substance can be utilized in ophtalmology in such indications as the support of resorption processes in the eye, in particular of exudates, cataracts of diverse ethiology, atero- and arteriosclerotic changes of the vessels of the retina and chorioidea, degenerative processes on the retina, beginning cataracts, mucotic conjuntivites and ceratidites.
Claims
1. Eye mstillation based on the iodine anion characterized in that it contains from 0.01 to 5 weight percent of potassium iodide, from 0.0005 to 0.1 weight percent of a conservation agent, from 0.001 to 2 weight percent of ancillary substances maintaining pH ofthe solution in the range from 5 to 8.0 and the rest to 100 weight percent is sterilized distilled water.
2. Eye instillation based on the iodine anion according to Claim 1 characterized in that it ontains from 0.01 to 5 weight percent of sodium iodide.
3. Eye instillation based on the iodine anion according to Claims 1 and 2 characterized in that it contains from 0.01 to 5 weight percent of substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s.
4. Eye instillation based on the iodine anion according to Claims 1, 2 and 3 characterized in that the ancillary substances maintaining the viscosity of the solution in the range from 1 to 50 mPa.s are hydroxypropylmethylcellulose, polyvinyl alcohol, monooleate polyoxyethylenesorbitan and carboxyvinyl polymer individually or in mixture.
5. Eye instillation based on the iodine anion according to Claims 1, 2, 3 and 4 characterized in that the conservation additive is chlorhexidine acetate or chlorhexidine gluconate, chlorbutanol or carbetho pendetinium bromide.
6. Eye instillation based on the iodine anion according to Claims 1, 2, 3, 4 and 5 characterized in that the ancillary substances maintaining pH of the solution in the range from 5 to 8.0 are sodium chloride, boric acid, sodium tetraborate, sodium acetate, sodium edetate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium tiosulphate, sodium citrate, citric acid individually or in mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003214793A AU2003214793A1 (en) | 2002-02-11 | 2003-02-10 | Eye installation based on iodine anions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SKPUV0025-2002 | 2002-02-11 | ||
| SK252002 | 2002-02-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003068247A1 true WO2003068247A1 (en) | 2003-08-21 |
| WO2003068247B1 WO2003068247B1 (en) | 2003-10-16 |
Family
ID=27752153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SK2003/000004 WO2003068247A1 (en) | 2002-02-11 | 2003-02-10 | Eye installation based on iodine anions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003214793A1 (en) |
| CZ (1) | CZ14554U1 (en) |
| WO (1) | WO2003068247A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120083772A1 (en) * | 2010-09-30 | 2012-04-05 | Curveright Llc | Corneal treatment system and method |
| US20150126921A1 (en) * | 2012-03-29 | 2015-05-07 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
| US9149035B2 (en) * | 2005-12-14 | 2015-10-06 | Convatec Technologies, Inc. | Antimicrobial composition |
| EP2830637A4 (en) * | 2012-03-29 | 2016-03-16 | Cxl Ophthalmics Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| AU2013206810B2 (en) * | 2005-12-14 | 2016-04-21 | Convatec Technologies Inc. | Antimicrobial composition |
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
| US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
| US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO68773A2 (en) * | 1976-02-18 | 1980-06-15 | Intreprinderea De Medicamente "Biofarm",Ro | OPHTHALMIC MEDICINE |
| RU1803110C (en) * | 1990-07-17 | 1993-03-23 | Всесоюзный научно-исследовательский институт фармации | Method of ophthalmic drops preparation |
-
2003
- 2003-02-10 WO PCT/SK2003/000004 patent/WO2003068247A1/en not_active Application Discontinuation
- 2003-02-10 AU AU2003214793A patent/AU2003214793A1/en not_active Abandoned
- 2003-02-10 CZ CZ200415526U patent/CZ14554U1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO68773A2 (en) * | 1976-02-18 | 1980-06-15 | Intreprinderea De Medicamente "Biofarm",Ro | OPHTHALMIC MEDICINE |
| RU1803110C (en) * | 1990-07-17 | 1993-03-23 | Всесоюзный научно-исследовательский институт фармации | Method of ophthalmic drops preparation |
Non-Patent Citations (6)
| Title |
|---|
| DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1982, E.GEORGESCU E.A.: "Ophtalmic composition", XP002242096, Database accession no. 1982:24813 * |
| DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1994, S.A.VALEVKO E.A.: "Method of eye drops preparation", XP002242095, Database accession no. 1994:253367 * |
| DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1975, M.KOSTOLOWSKA E.A.: "Chlorhexidine and thiomersal for preservation of ophtalmic solutions", XP002242097, Database accession no. EMB-1975208585 * |
| FARMACJA POLSKA, vol. 30, no. 11, 1974, pages 993 - 999 * |
| R.KINGET: "la préparation de collyres aux iodures", JOURNAL DE PHARMACIE DE BELGIQUE, vol. 39, no. 6, 1984, pages 383 - 389, XP008017347 * |
| V.HENSCHEL: "Formulation et stabilisation de collyres magistraux", FARMACO, EDITIONE PRATICA, vol. 27, no. 2, 1972, pages 65 - 79, XP000912109 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9149035B2 (en) * | 2005-12-14 | 2015-10-06 | Convatec Technologies, Inc. | Antimicrobial composition |
| AU2013206810B2 (en) * | 2005-12-14 | 2016-04-21 | Convatec Technologies Inc. | Antimicrobial composition |
| US10493101B2 (en) | 2005-12-14 | 2019-12-03 | Convatec Technologies Inc. | Antimicrobial composition |
| US10285857B2 (en) | 2010-09-30 | 2019-05-14 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US11135090B2 (en) | 2010-09-30 | 2021-10-05 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US11033429B2 (en) | 2010-09-30 | 2021-06-15 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US20120083772A1 (en) * | 2010-09-30 | 2012-04-05 | Curveright Llc | Corneal treatment system and method |
| US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
| US10092594B2 (en) | 2012-03-29 | 2018-10-09 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
| US10729716B2 (en) | 2012-03-29 | 2020-08-04 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US9555111B2 (en) * | 2012-03-29 | 2017-01-31 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
| EP2830637A4 (en) * | 2012-03-29 | 2016-03-16 | Cxl Ophthalmics Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US20150126921A1 (en) * | 2012-03-29 | 2015-05-07 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
| US11497766B2 (en) | 2012-03-29 | 2022-11-15 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US11931291B2 (en) | 2012-03-29 | 2024-03-19 | Epion Therapeutics, Inc. | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
| US11286601B2 (en) | 2012-12-20 | 2022-03-29 | Convatec Technologies, Inc. | Processing of chemically modified cellulosic fibres |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003068247B1 (en) | 2003-10-16 |
| CZ14554U1 (en) | 2004-07-26 |
| AU2003214793A1 (en) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110066351A (en) | Alkylated cyclodextrin composition and its preparation and application | |
| CA2895102A1 (en) | Pre-mixed, ready-to-use pharmaceutical compositions | |
| EP1905453B1 (en) | Preservative composition for ophthalmic use | |
| WO2003068247A1 (en) | Eye installation based on iodine anions | |
| JP2018515592A (en) | Oxidized β-1,4-glucuronic acid oligomer and production method and use thereof | |
| HUE030221T2 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| CN112088898B (en) | Composition containing oxidation-reduction potential water and preparation method thereof | |
| JPH02304026A (en) | Liquid for peritoneal lavage | |
| CN113440645A (en) | Composite lysozyme liquid dressing for wound surface and preparation method thereof | |
| CN1293879C (en) | Freeze-dried powder injection of pantoprazole sodium and its preparation | |
| JP3636372B2 (en) | Mesna injection solution, process for producing the same, and medicament for avoiding side effects of oxyazaphospholine comprising the same | |
| US3577532A (en) | Disinfected antacid compositions and method for the preparation thereof | |
| CN101455683A (en) | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455684A (en) | Zhenshiming eye drops without bacteria inhibitor and preparation method thereof | |
| JPWO2019107569A1 (en) | Ophthalmic products | |
| TWI840445B (en) | Aqueous composition and use thereof, injection set, pharmaceutical composition and manufacturing method thereof, generation inhibition | |
| KR20170094791A (en) | A nasal composition containing sea water as stability-improving excipient | |
| CA2486571C (en) | Pharmaceutical composition | |
| US3322627A (en) | Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor | |
| EP0362277A1 (en) | Preservative free ophthalmic ointments | |
| CA2835013C (en) | Eye drops for treatment of conjunctivochalasis | |
| CN101947253B (en) | External compound preparation for curing tinea corporis as well as preparation method and content measuring method thereof | |
| CN102961331A (en) | Iodine-chitosan solution formula and preparation method thereof | |
| WO2002002122A1 (en) | Ophthalmological drops with anti-imflammatory effect based on a wide-spectrum antibiotic and a local glucocorticoid | |
| WO2009117302A1 (en) | Removal of substances in dialysis solutions and dialysis components by ion exchange adsorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| B | Later publication of amended claims |
Free format text: 20030807 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PUV2004-15526 Country of ref document: CZ |
|
| WWG | Wipo information: grant in national office |
Ref document number: PUV2004-15526 Country of ref document: CZ |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |